Skip to main
SOLV

Solventum Corporation (SOLV) Stock Forecast & Price Target

Solventum Corporation (SOLV) Analyst Ratings

Based on 11 analyst ratings
Buy
Strong Buy 27%
Buy 36%
Hold 27%
Sell 0%
Strong Sell 9%

Bulls say

Solventum is in a strong position to capitalize on the growing healthcare industry, with a diverse portfolio of products that address a variety of customer and patient needs. Its focus on material science, data science, and digital capabilities gives it a competitive edge in the market and potential for future growth. The company's recent 1Q26 results were strong, with organic growth and higher margins, and the 2028 financial targets show promise for continued success. The potential for offensive M&A and divestitures in the future also indicates strategic planning and a drive towards consistent growth.

Bears say

Solventum is facing significant challenges in its MedSurg segment, which saw a decline in operating margins of 470 basis points year-over-year. The company's tariff impact is expected to continue into FY26, potentially hindering the company's financial performance. Additionally, the company is facing increased competition and risks such as higher costs and lower growth in key markets, which could negatively impact its ability to generate profits and drive shareholder value.

Solventum Corporation (SOLV) has been analyzed by 11 analysts, with a consensus rating of Buy. 27% of analysts recommend a Strong Buy, 36% recommend Buy, 27% suggest Holding, 0% advise Selling, and 9% predict a Strong Sell.

This aggregate rating is based on analysts' research of Solventum Corporation and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Solventum Corporation (SOLV) Forecast

Analysts have given Solventum Corporation (SOLV) a Buy based on their latest research and market trends.

According to 11 analysts, Solventum Corporation (SOLV) has a Buy consensus rating as of Aug 9, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $90.45, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $90.45, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Solventum Corporation (SOLV)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.